The medium was changed on day 8, day 10, and day 13 of the differentiation induction, and it was performed by a method similar to that in Experimental Example 1 on day 8 and day 10 of the differentiation induction, and performed by a method similar to that for day 10 in Experimental Example 1 on day 13 of the differentiation induction. On day 8, day 10, and day 13 of the differentiation induction, evaluation compounds (compounds and concentrations of Experiment Nos. 2 to 9 shown in Table 7 below) were added by a method similar to that in Experimental Example 1 (two wells were used for experiment number 1, and one well was used for others).

[0113]

[Table 7]

| experiment number | compound | final concentration (μM) |
|---|---|---|
| 1 | untreated | - |
| 2 | compound A | 0.5 |
| 3 | Foretinib | 2 |
| 4 | Foretinib | 0.5 |
| 5 | ZM323881 | 2 |
| 6 | CP-673451 | 1 |
| 7 | CP-673451 | 0.3 |
| 8 | Crizotinib | 2 |
| 9 | Crizotinib | 0.5 |

[0114]

On day 17 of differentiation induction, dissociation into single cells, fixation, cardiomyocyte rate (sarcomeric α-actinin-positive cell rate) measurement, and non-cardiomyocyte rate measurement were performed by methods similar to those in Experimental Example 1. The cardiomyocyte rate increased (Fig. 15) and the non-cardiomyocyte rate decreased (Fig. 16) by the treatment with compound A, Foretinib, ZM323881, or CP-673451, Crizotinib, as compared with no treatment with compound (Fig. 16).

[0115]

Experimental Example 8. Verification of cardiomyocyte